These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 1729540)

  • 41. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
    Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
    Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immunotherapy in metastatic cancer of the kidney].
    Escudier B
    Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapidly progressive glomerulonephritis after immunotherapy for cancer.
    Parker MG; Atkins MB; Ucci AA; Levey AS
    J Am Soc Nephrol; 1995 Apr; 5(10):1740-4. PubMed ID: 7787140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
    Sherry RM; Pass HI; Rosenberg SA; Yang JC
    Cancer; 1992 Apr; 69(7):1850-5. PubMed ID: 1551067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
    Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
    Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
    Litwin MS; Fine JT; Dorey F; Figlin RA; Belldegrun AS
    J Urol; 1997 May; 157(5):1608-12. PubMed ID: 9112487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
    Négrier S; Philip T
    Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
    Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
    N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
    Huland E; Heinzer H; Huland H
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
    Hofmockel G; Langer W; Theiss M; Gruss A; Frohmüller HG
    J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytoreductive surgery for stage IV renal cell carcinoma.
    Bennett RT; Lerner SE; Taub HC; Dutcher JP; Fleischmann J
    J Urol; 1995 Jul; 154(1):32-4. PubMed ID: 7776449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regression of pulmonary and multiple skeletal metastases from renal cell carcinoma by nephrectomy and alpha-interferon therapy: a case report.
    Ibayashi K; Ando M; Gotoh E
    Jpn J Clin Oncol; 1993 Dec; 23(6):378-83. PubMed ID: 8283792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.